MultiTAA-Specific T Cells: A Novel Treatment for Cancer

T cell therapies are limited in their potential to treat cancer by their inability to target only a single antigen. While these therapies can initially provide a significant response, these treatments can eventually lead to tumor resistance through antigen escape mechanisms.

Explore a novel technique being introduced for targeting up to six antigens. The Multi-Antigen Targeted (MultiTAA) cell therapy approach is currently being utilized in clinical trials for treatment of hematological malignancies, displaying high safety and efficacy. Through this presentation you will gain insight into:

• The enhanced patient outcomes achieved by targeting multiple antigens through MultiTAA T cell therapies
• Notable process improvements carried out by Marker Therapeutics resulting in reduced manufacturing time, decreased contamination risks, and significant cost savings
• Applications of MultiTAA in ongoing clinical trials to treat patients with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL)